FDA Clearance Tracker · P130022-S069
HFX Dynamis System
Last checked: Nov 20, 2026Latest source record: Aug 18, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Aug 18, 2026
Approved
Time to decision
487 days
Received Apr 18, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P130022-S069
- Device name
- HFX Dynamis System
- Applicant
- Nevro Corporation
- Applicant location
- Redwood City, CA
- Received
- Apr 18, 2025
- Decided
- Aug 18, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P130022
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
This supplement (S069) requested approval for the next generation implantable pulse generator system referred to as the HFX Dynamis System. The HFX Dynamis System is designed to deliver a new stimulation therapy, Bolus 10kHz, and support expanded MRI access to allow for scanning with one broken conductor per percutaneous lead. The key changes approved in this supplement include: a new Implantable Pulse Generator model (IPG3500), an updated Patient Application (PTA10043, v3.0.0), and updated Clinician Programmer Software (v4.0). The device, as modified, will be marketed under the trade name HFX Dynamis System and is indicated as follows:The HFX Dynamis System, HFX iQ System and HFX Trial System are indicated as aids in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain, and leg pain. The HFX Dynamis System, HFX iQ System and HFX Trial System, when programmed to include a frequency of 10 kHz, are indicated as aids in the management of chronic intractable pain of the lower limbs, including unilateral or bilateral pain, associated with diabetic neuropathy. The HFX Dynamis System, HFX iQ System and HFX Trial System, when programmed to include a frequency of 10 kHz, are indicated as aids in the management of non-surgical refractory back pain (intractable back pain without prior surgery and not a candidate for back surgery). FDA's review of this PMA supplement also included the review and approval of a PCCP: Juno Predetermined Change Control Plan, Rev A., which includes two future firmware modifications: 1. Disabling the 1 MHz ASIC clock while in MRI Mode for the IPG3000 and IPG3500, to reduce RF artifacts in MRI images; and 2. Optimizing power consumption for bolus therapy programs by disabling the ASIC during the bolus Macro Off Time, applicable to the IPG3500 only.
Source documents
Other decisions for Nevro Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Senza Spinal Cord Stimulation (SCS) SystemPMA supplement
P130022-S042 · Decided Jan 18, 2022 · 180 days after receipt · Panel Track
Device type: Stimulator, spinal-cord, totally implanted for pain relief (LGW) · Neurology & Neurosurgery
2 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.